|Videos|February 17, 2016
- Gastrointestinal Cancers: mCRC (Issue 7)
- Volume 1
- Issue 7
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Author(s)Jonathan R. Strosberg, MD
The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Advertisement
Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Articles in this issue
over 9 years ago
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancerover 9 years ago
ERCC1 Expression Falls Short as Chemo Biomarker in mCRCover 9 years ago
Panitumumab Boosts Overall Survival in Chemorefractory mCRCover 9 years ago
Two Options Allows for Treatment Tailoring in Refractory CRCover 9 years ago
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRCAdvertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
2
Trial Data Show Efficacy, Tolerability of Nivolumab Plus Visogromab in MIBC
3
FDA Grants Orphan Drug Status to Novel CD33-Directed Immunotherapy for AML
4
Domvanalimab Combo Shows Enriched First-Line Efficacy in Advanced GI Cancers
5
